Abstract
Cytomegalovirus (CMV) infection is an established cause of morbidity and mortality in renal transplant recipients. CMV-seronegative (SN) recipients of allografts from seropositive donors appear to be particularly vulnerable to clinically apparent post-transplant CMV disease. Since CMV seropositivity increases with age, pediatric transplant candidates are a logical population in whom to consider establishment of pre-transplant immunity through vaccination. Results of a preliminary vaccine trial in 5 SN adult transplant candidates immunized with CMV Towne 125, an attenuated strain, are reported here. Antibody to CMV was detected by IFA 2-4 weeks after vaccination in all patients. No CMV was recovered from any patient, despite later immunosuppression. No vaccine-attributable clinical or laboratory abnormalities have occurred. Current status of vaccinees is as follows:
Vaccination may offer a safe means of production of CMV antibody in renal transplant candidates at risk for CMV infection.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Glazer, J., Friedman, H., Grossman, R. et al. 769 A CYTOMEGALOVIRUS VACCINE TRIAL IN RENAL TRANSPLANT CANDIDATES. Pediatr Res 12 (Suppl 4), 492 (1978). https://doi.org/10.1203/00006450-197804001-00774
Issue Date:
DOI: https://doi.org/10.1203/00006450-197804001-00774